Skip to content

Collection of epilepsy anti-seizure medication response information for artificial intelligence research

Development of a validated data lake of multimodal epilepsy cohort variables for artificial intelligence research

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12625000881437
Acronym
EpiCFAIR
Enrollment
6800
Registered
2025-08-13
Start date
2024-07-03
Completion date
2028-07-03
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This is a multi-centre retrospective data collection collaboration with Monash University acting as the co- ordinating organisation. People with epilepsy will be assessed for eligibility through screening of seizure clinic attendance lists and hospital medical records by their recruiting organisations. The recruiting organisations will enter the structured clinical information of their people with epilepsy into the cohort dataset. The data will be de-identified before being provided to Monash University for storage in the data warehouse.

Interventions

This study involves the collection of retrospective outcome information for new diagnosis epilepsy patients who have for a minimum of 1-year been taking their clinically prescribed initial anti-seizure medication regimen. There is no active involvement of participants in this study, as they will not be required to complete questionnaires or physical assessments, all data collected will be from from existent medical records including: changes to anti-seizure medication regimen (cessation of regim

This study involves the collection of retrospective outcome information for new diagnosis epilepsy patients who have for a minimum of 1-year been taking their clinically prescribed initial anti-seizure medication regimen. There is no active involvement of participants in this study, as they will not be required to complete questionnaires or physical assessments, all data collected will be from from existent medical records including: changes to anti-seizure medication regimen (cessation of regimen or commencement of substitution or combination regimen), pre-treatment clinical factors including: sex, age, history of epilepsy related comorbidities, number of pre-treatment seizure, age of commencement of treatment and commencement of seizures. No limit has been placed on the period of post-prescription observation, only a minimum of 1-year to meet assessment of seizure freedom requirements.

Sponsors

Monash University
Lead SponsorUniversity

Eligibility

Sex/Gender
All
Age
2 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Diagnosis of epilepsy consistent with International League Against Epilepsy Criteria, defined as either: - At least two seizures within the past 12 months before commencing their first ASM, or - One seizure within the past 6 months before commencing their first ASM and epileptiform discharges on electroencephalography (EEG), or presence of epileptogenic lesion on computed tomography (CT) or magnetic resonance imaging (MRI) Initiation of ASM therapy at 2 years or older Minimum 1-year of follow-up post ASM treatment commencement

Exclusion criteria

Consistently poor adherence to the prescribed ASM treatment Diagnosed with functional seizures or mixed epileptic and functional seizures

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026